Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Insulin Resistance Also Mediated by White Blood Cells

By BiotechDaily International staff writers
Posted on 13 Aug 2012
Image: False-color scanning electron micrograph (SEM) of a neutrophil (Photo courtesy of UC San Diego School of Medicine).
Image: False-color scanning electron micrograph (SEM) of a neutrophil (Photo courtesy of UC San Diego School of Medicine).
Researchers have now found that neutrophils play a role in mediating the development of insulin resistance, the central characteristic of type 2 diabetes. The discovery also provides a potential new treatment target.

Using live mouse models as well as cultured liver and fat cells, a study team based at the University of California, San Diego, School of Medicine (La Jolla, CA, USA) discovered that an enzyme secreted by neutrophils called neutrophil elastase (NE) impairs insulin signaling and boosts resistance. Conversely, deletion of NE in obese mice fed a high-fat diet improved insulin sensitivity. “These results are largely unexpected. Although several immune cells have been established in the etiology of insulin resistance, the role of neutrophils in this process has remained unclear until now,” said Da Young Oh, co-author and assistant project scientist in the laboratory of study leader Jerrold M. Olefsky, MD and professor of medicine.

Chronic low-grade inflammation is an important cause of systemic insulin resistance. Neutrophils are the first immune cells to respond to tissue inflammation and can promote chronic inflammation by helping to recruit additional white blood cells - macrophages. Oh noted that neutrophils were considered to be “transient infiltrates” incapable of sustaining chronic, low-grade inflammation. “Our studies now suggest neutrophils possess powerful immune modulatory effects,” Oh said. Specifically, neutrophils use NE to activate a signaling pathway that triggers macrophages to secrete proinflammatory cytokines. NE degrades IRS1, a key protein in the insulin-signaling pathway in both liver and fat cells. The scientists noted that although NE has been shown to degrade this protein in lung cancer cells, the effect on insulin target tissues such as liver and adipose is striking.

The insulin-mediating role of neutrophils makes them a new target for developing treatments of insulin resistance in particular and diabetes in general. “One could, in theory, take an NE activity inhibitory approach to reverse or improve insulin resistance,” Oh said, noting that NE inhibiting drugs are already used for treatment of emphysema in Japan and are being tested in the United States for both emphysema and type 1 diabetes.

The findings have been reported in the August 5, 2012, advance online edition of the journal Nature Medicine.

Related Links:

University of California, San Diego, School of Medicine



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.